Table 3 Multivariate analysis of MetS and its components for adverse pathological features using the logistic regression models in RP patients after PSM

NOCD

 MetS

2.505 (0.880–7.130)

0.085

 BMI

0.929 (0.452–1.911)

0.842

 Hypertension

0.854 (0.363–2.008)

0.718

 Hyperglycemia

0.667 (0.312–1.428)

0.297

 Hypertriglyceridemia

0.376 (0.179–0.792)

0.010

 Low HDL-C

1.191 (0.572–2.482)

0.640

Lymph node invasion

 MetS

2.144 (0.485–9.484)

0.315

 BMI

0.808 (0.294–2.222)

0.680

 Hypertension

0.612 (0.193–1.936)

0.403

 Hyperglycemia

0.774 (0.270–2.219)

0.634

 Hypertriglyceridemia

0.471 (0.161–1.378)

0.169

    Low HDL-C

0.977 (0.344–2.780)

0.966

High grade

 MetS

1.082 (0.392–2.992)

0.879

 BMI

1.655 (0.815–3.360)

0.163

 Hypertension

0.809 (0.353–1.855)

0.617

 Hyperglycemia

1.306 (0.624–2.730)

0.479

 Hypertriglyceridemia

0.558 (0.269–1.157)

0.117

    Low HDL-C

0.634 (0.303–1.325)

0.225

Upgrading

 MetS

0.565 (0.204–1.567)

0.273

 BMI

1.277 (0.629–2.590)

0.499

 Hypertension

0.672 (0.303–1.490)

0.328

 Hyperglycemia

1.014 (0.483–2.128)

0.971

 Hypertriglyceridemia

2.433 (1.175–5.036)

0.017

    Low HDL-C

0.869 (0.420–1.796)

0.704

Positive surgical margin

 MetS

0.729 (0.271–1.963)

0.531

 BMI

1.385 (0.691–2.776)

0.358

 Hypertension

1.080 (0.478–2.440)

0.853

 Hyperglycemia

1.140 (0.553–2.350)

0.723

 Hypertriglyceridemia

1.685 (0.837–3.396)

0.144

    Low HDL-C

0.985 (0.485–2.001)

0.968

ECE

 MetS

2.394 (0.841–6.810)

0.102

 BMI

0.972 (0.472–1.999)

0.938

 Hypertension

0.834 (0.355–1.960)

0.677

 Hyperglycemia

0.734 (0.344–1.567)

0.424

 Hypertriglyceridemia

0.374 (0.177–0.788)

0.010

    Low HDL-C

1.126 (0.540–2.349)

0.751

SVI

 MetS

3.630 (0.643–20.504)

0.145

 BMI

0.405 (0.125–1.310)

0.131

 Hypertension

0.684 (0.179–2.609)

0.579

 Hyperglycemia

0.870 (0.280–2.701)

0.810

 Hypertriglyceridemia

0.472 (0.136–1.634)

0.236

 Low HDL-C

0.645 (0.206–2.019)

0.451